COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices holds an emergency meeting on the Johnson & Johnson (Janssen) COVID-19 vaccine to review reports that six women aged 18-48 experienced a rare but serious condition involving blood clots and low…
The Food and Drug Administration urged health care facilities to transition away from using crisis capacity conservation strategies, such as decontamination or bioburden reduction, to extend the use of N95s and other similar disposable respirators.
The Food and Drug Administration authorized for emergency use the first prescription antibody test that allows individuals to collect a finger-stick dried blood sample at home for analysis at a Symbiotica laboratory when a health care provider deems it appropriate.
The Food and Drug Administration authorized several SARS-CoV-2 serial screening tests for asymptomatic individuals.
The Food and Drug Administration said that Moderna can add up to 50% more doses per vial of its COVID-19 vaccine. Moderna had been shipping 10-dose vials; the FDA’s change will enable shipments to contain up to 15 doses per vial.
The Federal Communications Commission adopted a report and order implementing changes to the COVID-19 Telehealth Program under the Consolidated Appropriations Act, which authorized an additional $249.95 million in funding for the program.
The Centers for Medicare & Medicaid Services released an article informing all Medicare providers and suppliers who requested and received COVID-19 Accelerated and Advance Payments that it began recovering those payments March 30, depending on the one-year anniversary of their first payment.
The Food and Drug Administration has launched a webpage on the impact of viral mutations on COVID-19 tests, including recommendations for clinical laboratory staff and health care providers using the tests.
The Food and Drug Administration recently issued an emergency use authorization for a next generation sequencing test to detect SARS-CoV-2 in respiratory specimens from individuals suspected of COVID-19 by their health care provider.
The Pfizer and Moderna COVID-19 vaccines reduced the risk of both asymptomatic and symptomatic SARS-CoV-2 infection by 90% at least two weeks after the second dose and by 80% at least two weeks after the first dose in a study of 3,950 vaccinated health care and other essential workers, the Centers…